IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note released on Sunday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Up 1.1 %

Shares of NASDAQ:IRIX opened at $1.78 on Friday. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The stock has a fifty day simple moving average of $1.67 and a two-hundred day simple moving average of $1.99. IRIDEX has a 12-month low of $1.27 and a 12-month high of $3.65. The stock has a market capitalization of $29.62 million, a price-to-earnings ratio of -2.66 and a beta of 0.80.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period in the previous year, the company posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.